India, Jan. 30 -- Shares of Tectonic Therapeutic Inc. (TECX) more than doubled on Thursday morning after the clinical-stage biotechnology company announced positive interim data from its ongoing Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction.
TECX is currently trading at $53.12, up $27.40 or 106.55%, on the Nasdaq. The stock opened its trading at $49.50 after closing Wednesday at $25.72. The stock has traded between $1.40 and $54.50 in the past 52-week period.
The interim analysis showed that TX45 resulted in a 17.9 percent reduction in pulmonary capillary wedge pressure or PCWP and over a 30 percent reduction in pulmonary vascular resistance or PVR in pati...